Written questions by Ribeiro-Addy.

What assessment he has made of the potential impact of a limited access to suitable (a) prosthetics and (b) wigs on ethnic minority patients; and what steps he is taking to improve access.

The current NHS Supply Chain Wigs Framework Agreement was awarded to 42 suppliers and provides a range of wigs, both real and synthetic, and headwear products to provide alternative choices to patients, as well as maintenance, styling, alteration, and repair services.Whilst there is availability of Afro Caribbean wigs through the currently awarded suppliers, NHS Supply Chain is aware that due to the regionality of suppliers and the nature of them being predominantly micro and small to medium enterprises in many instances, patient choice and access across the United Kingdom can be subject to regional variation.NHS Supply Chain acknowledges that there is a need to develop the framework offering to support an increase in accessibility to patients for Afro Caribbean products and services, and NHS Supply Chain is preparing to introduce enhanced specifications and a specific category for Afro Caribbean for the successor framework agreement due to launch on 1 February 2027.NHS Supply Chain’s new Prosthetics, Components and Associated products Framework Agreement is due to launch on 24 November 2025, to replace the current Artificial Limbs framework. The new framework will offer over 95,000 products delivered by 12 suppliers to provide clinical choice to meet patient need. Ensuring that a patient has a prosthetic limb which blends with their actual skin tone is part of the routine standard of care. NHS Supply Chain works closely with the leading national charities and has not had any issues raised concerning accessing appropriate skin tone.

What steps his Department is taking to ensure that people with female reproductive systems are informed about symptoms of (a) ovarian and (b) other gynaecological cancers through NHS cervical screening programmes.

NHS England works to ensure that core public information on screening is easily accessible and understandable to the public, and it regularly and systematically reviews this information.Earlier this year, NHS England updated its cervical screening guidance to include that cervical screening is not a check for other cancers of the reproductive system, such as ovary, womb, vulval, or vaginal cancer. This guidance is available at the following link:https://www.gov.uk/government/publications/cervical-screening-description-in-brief/cervical-screening-helping-you-decide--2The guidance advises that you should not wait to contact a general practitioner if you have any concerns.

What steps her Department has taken to ensure (a) GPs and (b) mental health professionals are trained in (i) identifying and (ii) responding to the (A) traumatic physical and emotional impacts of violence and abuse and (B) the specific consequences of abuse for Black and minoritised victims.

All National Health Service staff are required to complete mandatory safeguarding training which includes how to identify and respond to domestic abuse and sexual violence. This training is being revised and is due to be re-launched in early 2026. The training update will strengthen the importance of intersectional considerations, including helping staff to understand the impact of trauma and cultural barriers to discussing abuse.General practitioners, along with other clinicians in the NHS, support victims and survivors of abuse in a range of ways depending on diagnosis and individual needs. This may include treating abuse-related injuries, referral to mental health treatment, or referral to a psychological support service such as peer support.All mental health service providers are expected to embed the Patient and carer race equality framework. This mandatory framework supports trusts and providers to implement actions to reduce racial inequalities within their services. It will become part of Care Quality Commission inspections. The Framework is available at the following link:https://www.england.nhs.uk/publication/patient-and-carer-race-equality-framework/Most integrated care boards and NHS trusts have appointed domestic abuse and sexual violence leads. They comprise a national network of leaders who share good practice, identify issues and develop solutions to support victim and survivors, including those from Black and minority groups.

With reference to the Imkaan report entitled Why should our rage be tidy, published in November 2024, what steps his Department is taking to increase the diversity of the NHS therapeutic workforce.

The National Health Service has an incredibly diverse workforce with over 75% of roles filled by women and over 25% of roles filled by people from an ethnic minority background. We expect NHS organisations to work to address inequalities that exist in the workplace to ensure the best outcomes for patients. As part of the Equality, Diversity and Inclusion Improvement Plan, employers across the NHS must embed fair and inclusive recruitment processes and talent management strategies that target under representation and lack of diversity in the workforce. Local NHS leaders remain best placed to take an evidence-based approach to recruitment and resourcing decisions.

With reference to Imkaan’s report entitled Why Should Our Rage be Tidy, published in November 2024, what steps he is taking to ensure that the NHS is equipped to (a) identify and (b) appropriately respond to signs of domestic and sexual violence.

Imkaan’s report highlights the distinct and additional challenges faced by black and minoritised victims of domestic and sexual violence. All National Health Service staff are required to complete mandatory safeguarding training which includes how to identify and respond to domestic and sexual violence. This training is being revised and is due to be re-launched in early 2026. The training update will strengthen the importance of intersectional considerations, including helping staff to understand the impact of trauma and cultural barriers to discussing abuse.There are a wide range of healthcare services that victims and survivors can access including sexual assault referral centres, which provide medical, practical and emotional support to victims of sexual assault and onward referral to wider support services.National Health Service trusts and integrated care boards have appointed Domestic Abuse and Sexual Violence leads to review their policies, training and support systems for patients and staff. This network of leads is used to help share and promote good practice, identify issues and develop practical solutions to support both patients and staff affected by domestic abuse and sexual violence.

Whether his Department plans to support the domestic (a) collection and (b) processing of (i) blood, (ii) plasma, (iii) cells and (iv) tissues.

NHS Blood and Transplant (NHSBT) is responsible for blood services in England and also manages the NHS Organ Donor Register (ODR), which includes tissue donation for the supply of human tissue grafts for use in surgery. The Department provides Grant in Aid and seed funding to support NHSBT to grow and diversify donor bases, as well as its capacity to process collections.Between 1 April 2024 and 31 March 2025, NHSBT met 99.9% of hospital demand for red cells from domestic collections; the remaining 0.01% of units were imported from other United Kingdom blood services.The Department, NHSBT and NHS England worked together since 2021 to deliver an end-to-end domestic supply chain for plasma-based medicines, enabling UK plasma to be processed into lifesaving medications in specialist facilities in Europe. Since March 2025, this has increased self-sufficiency from 0% to 25% for immunoglobulins and from 0% to 80% for albumin.The Department’s stem cell programme supports diverse recruitment of UK donors onto the UK Stem Cell Register. A global pool of donors is needed to cover the Human Leukocyte Antigen (HLA) diversity of the population so NHSBT works with international stem cell registries to meet patient demand.NHSBT works to encourage people to consider signing the ODR including during the upcoming Organ Donation Week between 22 and 26 September 2025. However, there is no mandate for National Health Service establishments to acquire tissue from NHSBT therefore they can acquire from other sources, such as non-UK tissue banks.

Whether his Department plans to (a) bring forward modernised UK-specific legislative proposals for Substances of Human Origin (SoHO) and (b) (i) adopt and (ii) adapt relevant elements of the EU’s updated SoHO legislation.

The Substances of Human Origin (SoHO) Regulation Review Programme launched in 2024 to consider recent changes that the European Union has made to its SoHO Regulation ((EU) 2024/1938) as well as stakeholder proposals for legislation in this area. It is reviewing: patient safety; intra-United Kingdom and UK-EU supply of SoHO; innovation within the sector; and health inequalities.A key principle of the review is to maintain compatible high levels of minimum safety and quality standards for blood, blood components, tissues and cells, human breast milk, intestinal microbiota and blood preparations that are not used for transfusion, to support public health and the movement of SoHO. A targeted consultation, planned to launch by the end of 2025, will give stakeholders the opportunity to share views and highlight key issues and opportunities.

When his Department plans to consult on reforms to the UK’s Substances of Human Origin; and whether that consultation will include proposals on (a) innovation, (b) patient safety and (c) donor protection.

The Substances of Human Origin (SoHO) Regulation Review Programme launched in 2024 to consider recent changes that the European Union has made to its SoHO Regulation ((EU) 2024/1938) as well as stakeholder proposals for legislation in this area. It is reviewing: patient safety; intra-United Kingdom and UK-EU supply of SoHO; innovation within the sector; and health inequalities.A key principle of the review is to maintain compatible high levels of minimum safety and quality standards for blood, blood components, tissues and cells, human breast milk, intestinal microbiota and blood preparations that are not used for transfusion, to support public health and the movement of SoHO. A targeted consultation, planned to launch by the end of 2025, will give stakeholders the opportunity to share views and highlight key issues and opportunities.

With reference to Imkaan’s report entitled Why should our rage be tidy, published in November 2024, whether (a) black and (b) minoritised survivors of domestic abuse are informed of by and for support services by their GP.

Imkaan’s report highlights the distinct and additional challenges faced by black and minoritised victims of domestic abuse and sexual violence. The Government recognises that racial health inequalities are linked to broader socioeconomic factors. Tackling these inequalities is central to building a fairer health system where outcomes are not dictated by race or background. That is why NHS England has introduced a framework for integrated care boards (ICBs) to reduce disparities in outcomes and improve access to treatments.All National Health Service staff, including general practitioners (GPs), are required to complete mandatory safeguarding training which includes how to identify, support and respond to domestic abuse and sexual violence. Safeguarding Leads within local NHS trusts, ICBs and general practices are responsible for ensuring practitioners are offering appropriate professional advice, support, and assurance to prevent harm, including onward referrals to specialist support services. Commissioning of support services for victims of abuse should be tailored to meet the needs and demographics of the local population.

With reference to Imkaan’s report entitled Why Should Our Rage be Tidy, published in November 2024, what steps his Department has taken to help tackle the mental health impacts of violence and abuse on Black and minoritised survivors of violence against women and girls.

Imkaan’s report reinforces the fact that too many people, including Black and minoritised survivors of domestic abuse and sexual violence, are not receiving the mental health care they need, and that waits for mental health services are too long. We are determined to change that, which is why we have chosen to prioritise funding to expand NHS Talking Therapies. Survivors can access help and support through their general practitioner or by self-referring. Protecting and supporting victims and survivors of sexual abuse is a core priority for NHS England, delivered through a network of 48 specialist sexual assault referral centres (SARCs) across the country. NHS England commissions SARCs through a distinct national service specification including working with specialist support services, ensuring that children and young people up to the age of 18 years old receive trauma-informed, developmentally appropriate care and safeguarding support, and that adults receive tailored care that reflects their needs and rights, with clear referral pathways to health, justice, and specialist support services. This is in addition to support services commissioned by the Ministry of Justice and the Home Office.

What steps he is taking to ensure that women’s health is included in the Government's plans to reform the NHS.

The Government is committed to prioritising women’s health as we build a National Health Service fit for the future.Our focus is on turning the commitments in the Women's Health Strategy into tangible action, such as: providing emergency hormonal contraception free of charge at pharmacies on the NHS from October 2025; setting out how we will eliminate cervical cancer by 2040 through the new cervical cancer plan; and taking urgent action to tackle gynaecology waiting lists through the Elective Reform Plan.Through our 10-Year Health Plan, we are delivering our commitment that never again will women’s health be neglected. The three shifts will improve the care women receive. Hospital to community will mean women can access convenient, coordinated care closer to home through Neighbourhood Health Centres, by building on best practice examples such as Tower Hamlets women’s health hub. Analogue to digital will put more power and data in women’s hands and will make it easier to get more personalised support, book appointments and stay healthy. Treatment to prevention will mean faster and fairer access to life-saving prevention through human papilloma virus (HPV) self-sampling kits, and access to the HPV vaccine through community pharmacies.

What steps he is taking to support the development and expansion of Women’s Health Hubs.

Women’s health hubs are an effective model for improving access to and experiences of care for women. The women’s health hub in Tower Hamlets was included in the 10-Year Health Plan as a best practice example to guide the shift to neighbourhood health.We are supporting integrated care boards (ICBs) to continue improving their delivery of women’s health hubs, in line with their responsibility to commission services that meet the needs of their local populations. This includes support through the Network of Women’s Health Champions to share learning from existing women’s health hubs.

What steps he is taking with Cabinet colleagues to improve the quality of maternity care for women across the country.

An independent Investigation into National Health Service maternity and neonatal services has been launched to understand the systemic issues behind why so many women, babies and families experience unacceptable care. Baroness Amos has been appointed as Chair of the Independent Maternity and Neonatal Investigation and will be supported by a team of esteemed expert advisers, who will be selected following further engagement with families. The Chair is working with families to finalise the terms of reference for the investigation, and these will be published shortly. The Investigation will produce an initial set of national recommendations by December 2025.The Government is also establishing a National Maternity and Neonatal Taskforce, chaired by my rt. Hon. Friend, the Secretary of State for Health and Social Care, to be made up of a panel of experts and family, charity and staff representatives. The Taskforce will use the recommendations from the independent Investigation to develop a national plan to drive improvements across maternity and neonatal care. The Taskforce will work closely with families in developing the action plan, ensuring their voices are central to this work.Immediate action is also being taken to improve accountability and better identify safety concerns within maternity services. This includes: measures to hold the system to account;  a system to better identify safety concerns; rolling out a programme to all trusts to tackle discrimination and racism; and new best practice standards in maternal mortality.

Whether it is NHS policy to carry out an inquest if a patient dies within 48 hours of being admitted to hospital.

Inquests are not NHS policy but are instead a matter for coroners. All deaths in England (and Wales) that are not referred to a coroner are considered by an independent Medical Examiner. Where there are any concerns about healthcare provided to the deceased in the run up to the death, Medical Examiners can refer the case for further consideration via local clinical governance processes. The NHS’ approach to Learning from Deaths is set out in the National Guidance on Learning from Deaths. This is available at the following link:https://www.england.nhs.uk/publication/national-guidance-on-learning-from-deaths/.

, how many sickle cell patients have developed haemolysis due to receiving a blood transfusion with unmatched blood during the last 12 months.

Serious Hazards of Transfusion (SHOT) is the United Kingdom’s independent, professionally led haemovigilance scheme. SHOT collects and analyses information on adverse events and reactions in blood transfusion from all healthcare organisations that are involved in the transfusion of blood components and specific blood products in the United Kingdom. Further information on SHOT is available at the following link:https://www.shotuk.org/The latest data available on haemolytic transfusion reactions was published in the Annual SHOT Report 2024. The report reviews reactions reported to SHOT from January to December 2024, and is available at the following link:https://www.shotuk.org/shot-reports/annual-shot-report-2024/#annual-shotOver the year, based on the available data, a total of 51 haemolytic transfusion reactions were reported. No errors were reported during the provision of blood components, meaning in all cases blood was appropriately matched, including safe substitutions where necessary, according to the patient requirements and clinical situation, as per British Society for Haematology’s guidelines, which are available at the following link:https://b-s-h.org.uk/guidelines/guidelines

How many patients with (a) leukaemia and lymphoma, (b) myeloma, (c) other cancers, (d) myelodysplastic syndromes, (e) aplastic anemia, (f) thalassemia, (g) bleeding disorders and (h) other conditions which require regular blood transfusions have developed haemolysis due to receiving a blood transfusion with unmatched blood in the last 12 months.

Serious Hazards of Transfusion (SHOT) is the United Kingdom’s independent, professionally led haemovigilance scheme. SHOT collects and analyses information on adverse events and reactions in blood transfusion from all healthcare organisations that are involved in the transfusion of blood components and specific blood products in the United Kingdom. Further information on SHOT is available at the following link:https://www.shotuk.org/The latest data available on haemolytic transfusion reactions was published in the Annual SHOT Report 2024. The report reviews reactions reported to SHOT from January to December 2024, and is available at the following link:https://www.shotuk.org/shot-reports/annual-shot-report-2024/#annual-shotOver the year, based on the available data, a total of 51 haemolytic transfusion reactions were reported. No errors were reported during the provision of blood components, meaning in all cases blood was appropriately matched, including safe substitutions where necessary, according to the patient requirements and clinical situation, as per British Society for Haematology’s guidelines, which are available at the following link:https://b-s-h.org.uk/guidelines/guidelines

If he will ensure that (a) prioritisation for medical evacuation and treatment of children from Gaza is based solely on clinical urgency and medical need and (b) it is not contingent on the availability of private funding or charitable sponsorship.

The Government is working urgently to get some of the critically ill and injured children medically evacuated from Gaza.The United Kingdom is partnering with the World Health Organization (WHO), which works on the ground and plays a critical role in supporting medical evacuations from Gaza. Clinical leaders in the NHS are working to match Gazan children to a priority list of those needing specialist medical care, provided by medical specialists in Gaza to the WHO, where there is capacity within the NHS to treat them.Children will only be transferred to the UK where it is clinically safe to do so and in the interests of each individual patient. As such, we will ensure medical assessments are undertaken before they travel.The UK Government will meet all the costs of those evacuated as part of this process.

What assessment his Department has made of the potential impact of the wholesale price increase of Mounjaro on patients managing (a) obesity and (b) type 2 diabetes.

As we shift the focus from treatment to prevention through our 10 Year Health Plan, we are determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.NHS England has worked with Eli Lilly to ensure that the list price increase will not affect National Health Service commissioning of tirzepatide in England as a treatment for eligible patients, and we remain committed to the rollout of this medicine as a weight loss treatment based on clinical priority. This will enable 220,000 eligible people to access the medication over the first three years. Not everyone who wants tirzepatide will be able to access it at first, and the initial eligibility criteria will be for people with a body mass index of 40 or more in addition to four or more qualifying comorbidities.Scotland, Wales, and Northern Ireland have also entered equivalent agreements to maintain their current commissioning approaches.Pricing in the private market is a matter for Eli Lilly and for private providers. Private patients who are impacted by price increases should discuss any concerns with their private provider. This includes their options regarding payment plans, alternative treatments, and/or stopping or tapering off their current medication. Eli Lilly is working with private providers to support continued patient access.

How many sickle cell patients have died due to complications due to sickle cell in the last 12 months.

The Department of Health and Social Care does not hold this information. NHS England does not hold or have access to data that would accurately represent the number of sickle cell patients that have died due to complications due to sickle cell disorder (SCD) in the last 12 monthsThe National Disease Registration Service, part of NHS England, is expanding its rare disease collection to include patients with SCD in England. This will form a comprehensive national dataset to enable improved understanding of patient pathways for SCD, support planning and commissioning of services and improve patient outcomes.

What recent discussions he has had with the NHS on its policy of informing Sickle Cell patients when they are not given Ro matched blood.

DHSC are working in partnership with NHS Blood and Transplant, NHS England and the National Blood Transfusion Committee to deliver on the recommendations detailed in the infected blood inquiry, which includes improving digital patient records and communications for patients receiving transfusions. A blood genotyping programme has also been introduced, enabling detection of previously undetectable antibodies that could cause complications. To meet the clinical need to provide better matched blood for patients with conditions like sickle cell disorder, NHS Blood and Transplant is actively recruiting donors from Black heritage backgrounds.